Journal of Clinical Endocrinology & Metabolism, Vol 79, 703-706, Copyright © 1994 by Endocrine Society

ARTICLES

The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness

AL Dallob, NS Sadick, W Unger, S Lipert, LA Geissler, SL Gregoire, HH Nguyen, EC Moore and WK Tanaka
Merck Research Laboratories, Rahway, New Jersey 07065.

The effects of the 5 alpha-reductase inhibitor, finasteride, on scalp skin testosterone (T) and dihydrotestosterone (DHT) levels were studied in patients with male pattern baldness. In a double blind study, male patients undergoing hair transplantation were treated with oral finasteride (5 mg/day) or placebo for 28 days. Scalp skin biopsies were obtained before and after treatment for measurement of T and DHT by high pressure liquid chromatography-RIA. In 10 male subjects studied at baseline, mean (+/- SEM) DHT levels were significantly higher in bald (7.37 +/- 1.24 pmol/g) compared to hair-containing (4.20 +/- 0.65 pmol/g) scalp, whereas there was no difference in mean T levels at baseline. In bald scalp from 8 patients treated with finasteride, the mean DHT concentration decreased from 6.40 +/- 1.07 pmol/g at baseline to 3.62 +/- 0.38 pmol/g on day 28. Scalp T levels increased in 6 of 8 subjects treated with finasteride. Finasteride decreased the mean serum DHT concentration from 1.36 +/- 0.18 nmol/L (n = 8) at baseline to 0.46 +/- 0.10 nmol/L on day 28 and had no effect on serum T. There were no significant changes in scalp or serum T or DHT in placebo-treated patients. In this study, male subjects treated with 5 mg/day finasteride for 4 weeks had significantly decreased concentrations of DHT in bald scalp, resulting in a mean level similar to the baseline levels found in hair-containing scalp.

This article has been cited by other articles:

				E. P. Gelmann Molecular Biology of the Androgen Receptor J. Clin. Oncol., July 1, 2002; 20(13): 3001 - 3015. [Abstract] [Full Text] [PDF]

				H. Vierhapper, P. Nowotny, H. Maier, and W. Waldhausl Production Rates of Dihydrotestosterone in Healthy Men and Women and in Men with Male Pattern Baldness: Determination by Stable Isotope/Dilution and Mass Spectrometry J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5762 - 5764. [Abstract] [Full Text] [PDF]

				R. A. Kazin, N. R. Lowitt, and M. H. Lowitt Update in Dermatology Ann Intern Med, July 17, 2001; 135(2): 124 - 132. [Full Text] [PDF]

				Y. Asada, T. Sonoda, M. Ojiro, S. Kurata, T. Sato, T. Ezaki, and S. Takayasu 5{{alpha}}-Reductase Type 2 Is Constitutively Expressed in the Dermal Papilla and Connective Tissue Sheath of the Hair Follicle in Vivo But Not during Culture in Vitro J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2875 - 2880. [Abstract] [Full Text] [PDF]

				E. Hawk, R. A. Breslow, and B. I. Graubard Male Pattern Baldness and Clinical Prostate Cancer in the Epidemiologic Follow-Up of the First National Health and Nutrition Examination Survey Cancer Epidemiol. Biomarkers Prev., May 1, 2000; 9(5): 523 - 527. [Abstract] [Full Text]

				P. Moghetti, F. Tosi, A. Tosti, C. Negri, C. Misciali, F. Perrone, M. Caputo, M. Muggeo, and R. Castello Comparison of Spironolactone, Flutamide, and Finasteride Efficacy in the Treatment of Hirsutism: A Randomized, Double Blind, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 89 - 94. [Abstract] [Full Text]

				D. Thiboutot Propecia Dosages Arch Dermatol, November 1, 1999; 135(11): 1417 - 1417. [Full Text] [PDF]

				V. H. Price Treatment of Hair Loss N. Engl. J. Med., September 23, 1999; 341(13): 964 - 973. [Full Text] [PDF]

				D. Deplewski, S. Liao, and R. L. Rosenfield Preputial Sebocyte 5{alpha}-Reductase Isoform Specificity Endocrinology, October 1, 1997; 138(10): 4416 - 4420. [Abstract] [Full Text] [PDF]

				J. I. Schwartz, W. K. Tanaka, D. Z. Wang, D. L. Ebel, L. A. Geissler, A. Dallob, B. Hafkin, and B. J. Gertz MK-386, an Inhibitor of 5{alpha}-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum without Affecting Dihydrotestosterone Concentrations in Semen J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1373 - 1377. [Abstract] [Full Text] [PDF]